3.22 0.07 (2.22%)
557.7K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 10,500 | 10,500 | - | - | Restricted Stock Units | |
| Andrea J. Corcoran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 44,367 | 44,366 | - | - | Restricted Stock Units | |
| Andrea J. Corcoran | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 16,102 | 717,307 | - | 3.1 | 49,272 | Common Stock |
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 10,500 | 733,409 | - | - | Common Stock | |
| Andrea J. Corcoran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 44,367 | 722,909 | - | - | Common Stock | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 173,467 | 290,024 | - | - | Common Stock | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 99,517 | 389,541 | - | - | Common Stock | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 440,000 | 440,000 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 99,518 | 99,518 | - | - | Restricted Stock Units | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 173,467 | 173,466 | - | - | Restricted Stock Units | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 88,601 | 300,940 | - | 3.1 | 271,119 | Common Stock |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 120,100 | 120,100 | - | - | Stock Option (Right to Buy) | |
| Wayne Foster | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 54,190 | - | - | Common Stock | |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,000 | 62,190 | - | - | Common Stock | |
| Wayne Foster | EVP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 12,062 | 50,128 | - | 3.1 | 36,910 | Common Stock |
| Wayne Foster | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 33,333 | - | - | Restricted Stock Units | |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,000 | 8,000 | - | - | Restricted Stock Units | |
| Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 46,800 | 84,272 | - | - | Common Stock | |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,250 | 11,250 | - | - | Restricted Stock Units | |
| Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 46,800 | 46,800 | - | - | Restricted Stock Units | |
| Janet Hammond | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 14,134 | 81,388 | - | 3.1 | 43,250 | Common Stock |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,250 | 95,522 | - | - | Common Stock | |
| Maria Arantxa Horga | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 41,533 | 41,533 | - | - | Restricted Stock Units | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 9,750 | 9,750 | - | - | Restricted Stock Units | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 192,800 | 192,800 | - | - | Stock Option (Right to Buy) | |
| Maria Arantxa Horga | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 41,533 | 67,197 | - | - | Common Stock | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 9,750 | 76,947 | - | - | Common Stock | |
| Maria Arantxa Horga | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 16,071 | 60,876 | - | 3.1 | 49,177 | Common Stock |
| John Vavricka | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 11,517 | 52,081 | - | 3.1 | 35,242 | Common Stock |
| John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 54,848 | - | - | Common Stock | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,750 | 63,598 | - | - | Common Stock | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 132,800 | 132,800 | - | - | Stock Option (Right to Buy) | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,750 | 8,750 | - | - | Restricted Stock Units | |
| John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 33,333 | - | - | Restricted Stock Units | |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 15 Jan 2025 | 15,000 | 466,897 | - | 3.2 | 47,885 | Common Stock |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 15 Jan 2025 | 10,000 | 476,897 | - | 3.4 | 33,614 | Common Stock |
| M. Berger Franklin | Director | Sale of securities on an exchange or to another person at price $ 2.85 per share. | 10 Dec 2024 | 359,606 | 451,897 | - | 2.8 | 1,023,475 | Common Stock |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 17 Sep 2024 | 1,841 | 5,866,025 | - | 4.0 | 7,367 | Common Stock |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 17 Sep 2024 | 22,187 | 5,867,866 | - | 4.0 | 89,469 | Common Stock |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 17 Sep 2024 | 33,941 | 5,890,053 | - | 4.0 | 137,318 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Bruno Lucidi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Bruno Lucidi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Polly A. Murphy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Polly A. Murphy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Jerome M. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Jerome M. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Bruce Polsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Bruce Polsky | Director | Sale of securities on an exchange or to another person at price $ 3.49 per share. | 20 Jun 2024 | 17,544 | 65,606 | - | 3.5 | 61,144 | Common Stock |
| Bruce Polsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 811,503 | - | 0 | Common Stock | |
| Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Bruce Polsky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Bruce Polsky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 83,150 | - | 0 | Common Stock | |
| Barbara G. Duncan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Barbara G. Duncan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 33,150 | - | 0 | Common Stock | |
| Bruno Lucidi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 83,150 | - | 0 | Common Stock | |
| Bruno Lucidi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Polly A. Murphy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Polly A. Murphy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 56,445 | - | 0 | Common Stock | |
| Jerome M. Adams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 33,150 | - | 0 | Common Stock | |
| Jerome M. Adams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 05 Jun 2024 | 1,006 | 5,923,994 | - | 4 | 4,024 | Common Stock |
| John Vavricka | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 11,819 | 21,515 | - | 3.8 | 45,420 | Common Stock |
| Vavricka John | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 66,666 | - | - | Restricted Stock Units | |
| Janet Hammond | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 14,029 | 35,362 | - | 3.8 | 53,913 | Common Stock |
| Foster Wayne | EVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 12,477 | 20,857 | - | 3.8 | 47,904 | Common Stock |
| Arantxa Maria Horga | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 15,870 | 25,664 | - | 3.8 | 60,963 | Common Stock |
| Andrea J. Corcoran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 44,367 | 686,051 | - | - | Common Stock | |
| J. Andrea Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Hammond Janet | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 225,200 | 225,200 | - | - | Stock Option (Right to Buy) | |
| Vavricka John | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 132,800 | 132,800 | - | - | Stock Option (Right to Buy) | |
| Sommadossi Jean-Pierre | Director, President, CEO, and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 173,467 | 346,933 | - | - | Restricted Stock Units | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Sale of securities on an exchange or to another person at price $ 3.85 per share. | 31 Jan 2024 | 56,910 | 116,557 | - | 3.8 | 218,819 | Common Stock |
| Wayne Foster | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 66,666 | - | - | Restricted Stock Units | |
| Andrea Corcoran J. | See Remarks | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 15,843 | 670,208 | - | 3.8 | 60,915 | Common Stock |
| J. Corcoran Andrea | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 44,367 | 88,733 | - | - | Restricted Stock Units | |
| Vavricka John | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 33,334 | - | - | Common Stock | |
| Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 46,800 | 93,600 | - | - | Restricted Stock Units | |
| Maria Arantxa Horga | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 41,534 | 41,534 | - | - | Common Stock | |
| Sommadossi Jean-Pierre | Director, President, CEO, and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 173,467 | 173,467 | - | - | Common Stock | |
| Arantxa Maria Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 192,800 | 192,800 | - | - | Stock Option (Right to Buy) | |
| Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 46,800 | 49,391 | - | - | Common Stock | |
| Foster Wayne | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 33,334 | - | - | Common Stock | |
| Maria Horga Arantxa | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 41,534 | 83,066 | - | - | Restricted Stock Units | |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 120,100 | 120,100 | - | - | Stock Option (Right to Buy) | |
| Sommadossi Jean-Pierre | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 448,000 | 448,000 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Bruce Polsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Bruce Polsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Bruno Lucidi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Bruno Lucidi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Polly A. Murphy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Polly A. Murphy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Jerome M. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Jerome M. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 133,100 | 133,100 | - | - | Restricted Stock Units | |
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 186,300 | 186,300 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 520,400 | 520,400 | - | - | Restricted Stock Units | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 728,600 | 728,600 | - | - | Stock Option (Right to Buy) | |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 196,600 | 196,600 | - | - | Stock Option (Right to Buy) | |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,400 | 140,400 | - | - | Restricted Stock Units | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 124,600 | 124,600 | - | - | Restricted Stock Units | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 174,500 | 174,500 | - | - | Stock Option (Right to Buy) | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 5.16 per share. | 11 Nov 2022 | 16,166 | 778,353 | - | 5.2 | 83,352 | Common Stock |
| Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 5.15 per share. | 11 Nov 2022 | 25,500 | 794,519 | - | 5.2 | 131,333 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Bruce Polsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Bruno Lucidi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Polly A. Murphy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Jerome M. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 181,000 | 181,000 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 378,033 | 378,033 | - | - | Stock Option (Right to Buy) | |
| Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Jerome M. Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 56,670 | 56,670 | - | - | Stock Option (Right to Buy) | |
| Andrea J. Corcoran | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 148,850 | 148,850 | - | - | Stock Option (Right to Buy) | |
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 640,000 | 640,000 | - | - | Stock Option (Right to Buy) | |
| Wayne Foster | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 71,750 | 71,750 | - | - | Stock Option (Right to Buy) | |
| Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 160,050 | 160,050 | - | - | Stock Option (Right to Buy) | |
| Maria Arantxa Horga | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 145,500 | 145,500 | - | - | Stock Option (Right to Buy) | |
| John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 117,300 | 117,300 | - | - | Stock Option (Right to Buy) | |
| Andrea J. Corcoran | See Remarks | 03 Nov 2020 | 100,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Andrea J. Corcoran | See Remarks | 03 Nov 2020 | 33,004 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Andrea J. Corcoran | See Remarks | 03 Nov 2020 | 133,004 | 633,004 | - | - | Common Stock | ||
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 24.00 per share. | 03 Nov 2020 | 41,666 | 820,019 | - | 24 | 999,984 | Common Stock |
| Franklin M. Berger | Director | 03 Nov 2020 | 759,606 | 778,353 | - | - | Common Stock | ||
| Franklin M. Berger | Director | 03 Nov 2020 | 131,578 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Franklin M. Berger | Director | 03 Nov 2020 | 60,540 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Franklin M. Berger | Director | 03 Nov 2020 | 35,474 | 0 | - | - | Series D-1 Convertible Preferred Stock | ||
| Franklin M. Berger | Director | 03 Nov 2020 | 132,014 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Franklin M. Berger | Director | 03 Nov 2020 | 400,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | 03 Nov 2020 | 750,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Jean-Pierre Sommadossi | Director, President, CEO, and Chairman | 03 Nov 2020 | 750,000 | 5,925,000 | - | - | Common Stock | ||
| Andrew A. F. Hack | Director | 03 Nov 2020 | 1,982,469 | 0 | - | - | Series D-1 Convertible Preferred Stock | ||
| Andrew A. F. Hack | Director | 03 Nov 2020 | 3,383,190 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Andrew A. F. Hack | Director | Purchase of securities on an exchange or from another person at price $ 24.00 per share. | 03 Nov 2020 | 250,000 | 5,615,659 | - | 24 | 6,000,000 | Common Stock |
| Andrew A. F. Hack | Director | 03 Nov 2020 | 5,365,659 | 5,365,659 | - | - | Common Stock | ||
| John Vavricka | Chief Commercial Officer | 03 Nov 2020 | 82,508 | 0 | - | - | Series B Convertible Preferred Stock | ||
| John Vavricka | Chief Commercial Officer | 03 Nov 2020 | 82,508 | 82,508 | - | - | Common Stock | ||
| Polly A. Murphy | Director | 03 Nov 2020 | 7,122 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Polly A. Murphy | Director | 03 Nov 2020 | 4,173 | 0 | - | - | Series D-1 Convertible Preferred Stock | ||
| Polly A. Murphy | Director | 03 Nov 2020 | 11,295 | 11,295 | - | - | Common Stock | ||
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Bruce Polsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Andrew A. F. Hack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Wayne Foster | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Isaac Cheng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Bruno Lucidi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) |